TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01558310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. Group B will receive placebo at Week 0 and 4, and ustekinumab at weeks 12, 16, 28, 40 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab
Description: Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. Group B will receive placebo at Week 0 and 4, and ustekinumab at weeks 12, 16, 28, 40 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
Study: NCT03089125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyspnea Intervention
Description: Dyspnea intervention will be administered over two sessions~Patients will receive:~* Psychoeducation~* Relaxation training for reducing physiological stress~* Behavioral techniques for managing acute breathlessness

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Patients will receive any usual care for their dyspnea as deemed appropriate by their clinicians

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients will receive any usual care for their dyspnea as deemed appropriate by their clinicians
Study: NCT02424084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Extracorporeal Shock Wave Therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Extracorporeal Shock Wave Therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Extracorporeal Shock Wave Therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Extracorporeal Shock Wave Therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Extracorporeal Shock Wave Therapy
Study: NCT05850039

Intervention type: OTHER
Intervention: Sampling
Description: Sample collection: a small fragment of atrial wall will be collected

Intervention type: OTHER
Intervention: Sampling
Description: Sample collection: a small fragment of atrial wall will be collected

Intervention type: OTHER
Intervention: Sampling
Description: Sample collection: a small fragment of atrial wall will be collected
Study: NCT00998400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT in combination with WBT and life style modification
Description: CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems. The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others. CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
Study: NCT01329354

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous effector lymphocytes expanded ex-vivo
Description: Maintenance therapy with Rituximab every two months is the standard of care for patients with follicular lymphoma after induction therapy. The intervention consists on the administration of autologous effector lymphocytes expanded ex-vivo every two Rituximab administrations.
Study: NCT01772784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phenolic acids
Description: Phenolic acids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phenolic acids
Description: Phenolic acids

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phenolic acids
Description: Phenolic acids

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phenolic acids
Description: Phenolic acids
Study: NCT02032160

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix B IM injection - 20ug
Description: Engerix B IM injection - 20ug At 0, 1 and 6 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fendrix IM injection - 20ug
Description: Fendrix IM injection - 20ug At 0, 1 and 6 months
Study: NCT04839029

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bipolar En bloc TURBT
Description: patients subjected to Bipolar resection of bladder tumor by Collins loop

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar En bloc TURBT
Description: patients subjected to Monopolar resection of bladder tumor by Collins loop (hot Knife)
Study: NCT01191840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Duration
Study: NCT01910623

Intervention type: OTHER
Intervention: Health Related Quality of Life (HRQOL) measures
Study: NCT00751764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Study: NCT03073564

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endurance test for upper limbs
Description: Subjects will initially perform maximal incremental cardiopulmnar test of upper limbs to assess the suggestion of dynamic hyperinflation (DH). After that, it will be randomized, for those who presented DH, to perform the endurance test with and without the use of positive expiratory pressure mask.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional test
Description: The 6-min pegboard and ring test (6PBRT) will be performed under usual breathing and during application of the EPAP mask. In this condition will be evaluated the presence of dynamic hyperinflation, perception of effort and dipnea, in addition to exercise capacity.
Study: NCT00672854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid, 20% Intravenous Emulsion
Description: It is made up of 20% Soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection
Study: NCT00160771

Intervention type: BEHAVIORAL
Intervention: Joint Motion Analysis
Description: Joint motion will be recorded for analysis.
Study: NCT00208949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF, solution given subcutaneously twice per day, total dosage varies by weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF, solution given subcutaneously twice per day, total dosage varies by weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF
Description: GM-CSF, solution given subcutaneously twice per day, total dosage varies by weight.
Study: NCT01760603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ISFF
Description: Ischia spinous fascia fixation surgery was performed on patient with pelvic organ prolapse.
Study: NCT01669109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Study: NCT03108365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Axiostat
Description: Axiostat® is a sterile, non-absorbable haemostatic dressing intended to control profuse bleeding within minutes of application by providing an active mechanical barrier to the wound site.~Axiostat® stops moderate to severe bleeding due to cuts, abrasions, lacerations, venous/arterial punctures and more. Mechanism of action is such that Axiostat® is an extremely positive dressing that becomes very sticky in the presence of negatively charged blood and thus seals the wound area.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cotton Gauze
Description: Size: 1 x 1 cm
Study: NCT02346201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Two 5mg methylphenidate over-encapsulated drug taken twice a day for 6 months (total of 20 mg methylphenidate per day), and psychosocial intervention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two over-encapsulated placebo taken twice a day for 6 months and psychosocial intervention
Study: NCT03420066

Intervention type: OTHER
Intervention: Retrospective data collection
Description: Retrospective collection of data recorded as standard of care for patients that were implanted with the Nexus device as part of Compassionate Use duly authorized according to country specific regulations.
Study: NCT03381248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooled Radiofrequency
Description: Delivery of energy to ablate sensory nerves via cooled radiofrequency probe.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid Injection
Description: Delivery of hyaluronic acid into knee by injection with needle to reduce knee pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crossover from Hyaluronic Acid Injection to Cooled Radiofrequency
Description: Delivery of hyaluronic acid into knee by injection with needle to reduce knee pain. After 6 months, qualifying subjects in this group will have the option to crossover to receive cooled radiofrequency treatment.
Study: NCT03516747

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pre operative parathyroid hormone level measurement
Description: At the clinic, the participants will undergo ultrasound examination with fine needle aspiration. The aspirated material will be sent for parathyroid hormone level measurement.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pre operative parathyroid cytology
Description: At the clinic, the participants will undergo neck ultrasound examination with fine needle aspiration. The aspirated material will be sent for cytology examination.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: parathyroid hormone level measurement
Description: At surgery, after the pathologic gland is excised , the gland will be aspirated. The material will be sent for parathyroid hormone level measurement.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: parathyroid cytology
Description: At surgery, after the pathologic gland is excised , it will be aspirated again for cytologic examination.
Study: NCT03401905

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low frequency
Description: A dry needling on trapezius muscle is performed, until two local twitch responses are obtained. The needle is kept inside the trigger point, as it will be the negative electrode, and an adhesive electrode will be added as the positive one. After that, a low frequency TENS is applied, at 2 Hz frequency and 120 microseconds of pulse width.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High frequency
Description: A dry needling on trapezius muscle is performed, until two local twitch responses are obtained. The needle is kept inside the trigger point, as it will be the negative electrode, and an adhesive electrode will be added as the positive one. After that, a high frequency TENS is applied, at 12o Hz frequency and 200 microseconds of pulse width.
Study: NCT00422656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Study: NCT05432843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Patients receive for one week Pregabalin 75 mg and 7 weeks Pregabalin 150 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive a treatment with placebo for 8 weeks
Study: NCT03043378

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants complete three questionnaires at consultation visit.
Study: NCT03262974

Intervention type: DIAGNOSTIC_TEST
Intervention: PCR
Description: PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: PCR
Description: PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: HPLC-UV
Description: HPLC-UV

Intervention type: DIAGNOSTIC_TEST
Intervention: HPLC-UV
Description: HPLC-UV
Study: NCT02465411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G4 or later generation
Description: Continuous glucose monitoring with DexCom G4 platina or later generations
Study: NCT00914433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 1100
Description: 1 dose only increasing dose
Study: NCT00604838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AL-SENSE Diagnostic Absorbent Panty liner
Description: worn for 12 hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AL-SENSE Diagnostic Absorbent Panty liner
Description: Diagnostic Absorbent Panty liner (AL-SENSE Amniotic Leak Test Kit), developed by Common Sense Ltd worn for 12 hours
Study: NCT03373526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: The Inspiratory Muscle Training will be perform using using the Power Breathe® device, during 20 minutes daily, five times a week. The protocol will be performed in the sitting position with an established load of 40% of maximal inspiratory pressure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Training
Description: The aerobic physical training will be perform using a cycle ergometer, during 20 minutes daily, five times a week, with moderate intensity (50-70% of reserve heart rate).
Study: NCT04385849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Sterile saline solution
Study: NCT03373526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: The aerobic physical training will be perform using a cycle ergometer, during 20 minutes daily, five times a week, with moderate intensity (50-70% of reserve heart rate).
Study: NCT01423682

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Eccentric exercise
Description: Patients and healthy subjects will perform an eccentric exercise during which a weight is lifted along the body and lowered with an extended arm at a slow speed. Weight is determined, based on pain in patients and based on force in healthy subjects.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric exercise
Description: Patients and healthy subjects will perform an eccentric exercise during which a weight is lifted along the body and lowered with an extended arm at a slow speed. Weight is determined, based on pain in patients and based on force in healthy subjects.
Study: NCT00710606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NuvaRing
Description: Obese subjects (BMI 30-39.9) will receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuvaRing
Description: Normal weight subjects will also receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
Study: NCT03652779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecarfarin 10mg
Description: Tecarfarin 10mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecarfarin 20mg
Description: two tecarfarin 10mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecarfarin 30mg
Description: three tecarfarin 10mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecarfarin 40mg
Description: four tecarfarin 10mg tablets
Study: NCT02298361

Intervention type: OTHER
Intervention: Health insurance outreach IT tools
Description: IT tools that support Community Health Centers in children's health insurance outreach efforts (insurance outreach IT tools), adapted from tools proven to support chronic disease management.
Study: NCT01564368

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: diffusion-weighted magnetic resonance imaging examination and subsequent radiologist interpretation
Study: NCT02991482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (MK-3475) is a potent and highly selective humanised monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumour regression and ultimately immune rejection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumour growth, as new nucleosides cannot be attached to the faulty nucleoside, resulting in apoptosis (cellular suicide).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine is a vinca alkaloid cytotoxic chemotherapy that is available in intravenous and oral preparations with EMA licenses in lung cancer and breast cancer. Vinorelbine blocks mitosis in phase G2-M, causing cell death in interphase or at the following mitosis.
Study: NCT02879448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amulet Left Atrial Appendage Occluder
Description: Transcatheter left atrial appendage closure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WATCHMAN Left Atrial Appendage Closure
Description: Transcatheter left atrial appendage closure
Study: NCT01696331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Reminder
Description: Sent TM reminder at beginning and end of each month that corresponded to required lab frequency. Patients were able to send autoresponses.
Study: NCT02301351

Intervention type: OTHER
Group type: OTHER
Intervention: Graphic Warning Label
Description: All packs provided will include FDA-approved graphic warning labels

Intervention type: OTHER
Group type: OTHER
Intervention: Text Warning Label
Description: All packs provided will include standard text warning labels
Study: NCT02462902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% albumin Infusion
Description: colloid, 5% albumin (250 ml over 15 to 30 minutes).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% sodium chloride solution
Description: 0.9% sodium chloride solution (total of 30ml/kg over 15 to 30 minutes)
Study: NCT04439643

Intervention type: DEVICE
Intervention: vascuCAP
Description: time to event and phenotype classification model

Intervention type: DEVICE
Intervention: vascuCAP
Description: time to event and phenotype classification model
Study: NCT01713725

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: * Two injections will be administered the first two weeks~* The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Omalizumab
Description: * Two injections will be administered the first two weeks~* The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: * Two injections will be administered the first two weeks~* The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Two injections will be administered the first two weeks~* The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks
Study: NCT01750879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peanut Flour
Description: Peanut Flour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oat Flour
Description: Oat Flour
Study: NCT01439607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone marrow and blood sampling
Description: Bone marrow and blood sampling
Study: NCT04167241

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Before and after right pneumonectomy or bi-lobectomy patients will receive echocardiography
Study: NCT04570917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online educational intervention to reduce ageism
Description: Participants in this group will go over multiple short videos covering the following content:1). Myths about aging, 2). Ageism and its negative effects, 3). Distorted views about aging among young adults, 4). Ageism during the COVID-19 pandemic, and 5). importance of reducing ageism among healthcare professionals. These will be multiple videos posted on the LMS (Blackboard). At the end of the lesson, they will be asked to briefly write what they learned on Blackboard as an assignment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online educational intervention to enhance cultural competance
Description: Participants in the control group will go over multiple short videos covering the following content: 1). Myths about cultural competence, 2) Cultural competence for health care professionals including dietitians, 3). Connecting culture and food, and 4). Importance of cultural competence in sports dietitians. At the end of the lesson, they will be asked to briefly write what they learned. These will be multiple videos posted on the LMS (Blackboard). At the end of the lesson, they will be asked to briefly write what they learned on Blackboard as an assignment.